Akero Therapeutics Inc

Akero Therapeutics — JP Morgan Healthcare Conference 2021

33 slides from Akero Therapeutics's conference presentation, Jan 11, 2021

  1. Slide 1: A Global Disease, A Pioneering Treatment

    Slide 1: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. JP Morgan Presentation January 2021

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    - CONFIDENTIAL - SAFE HARBOR This presentation may contain “forward - looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Compa ny”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditio

  3. Slide 3: Corporate Highlights

    Slide 3: Corporate Highlights

    - CONFIDENTIAL - CORPORATE HIGHLIGHTS 3 • Human FGF21 analog addresses all core aspects of NASH pathology • Engineered for optimal activity and convenient once - weekly dosing • Phase 2a BALANCED study results among strongest data in field: liver fat reduction coupled with improvements in histology,

  4. Slide 4: Extensive Development and Commercialization Experience

    Slide 4: Extensive Development and Commercialization Experience

    - CONFIDENTIAL - 4 EXTENSIVE DEVELOPMENT AND COMMERCIALIZATION EXPERIENCE INVOLVED IN 20+ MEDICINE APPROVALS Andrew Cheng, MD, PhD | President & CEO • 19 years at Gilead • Chief Medical Officer & HIV Division Head • Major role in 11 NDA/MAA approvals Kitty Yale | EVP & Chief Development Officer • Ov

  5. Slide 5: NASH: A Serious and Debilitating Multi-System Disease

    Slide 5: NASH: A Serious and Debilitating Multi-System Disease

    - CONFIDENTIAL - NASH: A SERIOUS AND DEBILITATING MULTI - SYSTEM DISEASE 5 An estimated 17 million Americans have NASH, with expectation that population will grow >50% by 2030 The number of NASH patients with advanced - stage fibrosis and cirrhosis is predicted to grow to 8 million in the US by 2030

  6. Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy, With Once-Weekly Dosing

    Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy, With Once-Weekly Dosing

    - CONFIDENTIAL - EFX ENGINEERING POTENTIALLY OPTIMAL FOR NASH EFFICACY, WITH CONVENIENT ONCE - WEEKLY DOSING 6 Key attributes Stanislaus, S et al. (2017) Endocrinology 158(5): 1314 - 27; Lee, S et al. (2018) Nature 553: 501 - 505; Kharitonenkov, A et al. (2007) Endocrinology 148(2)774 - 781 Akero pr

  7. Slide 7: EFX Acts on Two Major Sources of Liver Fat

    Slide 7: EFX Acts on Two Major Sources of Liver Fat

    - CONFIDENTIAL - EFX ACTS ON TWO MAJOR SOURCES OF LIVER FAT WITH POTENTIAL FOR OPTIMAL REDUCTION 7 Source of Liver Fat FGF Receptor EFX Activity Lipolysis FGFR1c x De Novo Lipogenesis FGFR2c FGFR3c x Sources of Fat Flowing into and Through Liver for NASH Patients Adipose Tissue: Lipolysis (40 - 50%)

  8. Slide 8: EFX Direct and Indirect Anti-Fibrotic Effects

    Slide 8: EFX Direct and Indirect Anti-Fibrotic Effects

    - CONFIDENTIAL - EFX DIRECT AND INDIRECT ANTI - FIBROTIC EFFECTS 8 Myofibrobl asts *Cited literature available on company website Direct Effect Indirect Effect Bao, L et al. (2018) Br J Pharmacol 175:3379 - 3393; Fisher, FM et al. (2014) Gastroenterology 147:1073 - 1083.e6; Jimenez, V et al. (2018)

  9. Slide 9: Phase 2a Trial (BALANCED) Design

    Slide 9: Phase 2a Trial (BALANCED) Design

    - CONFIDENTIAL - Screening Biopsy - Confirmed NASH Randomization 70mg EFX (n=20) 50mg EFX (n=20) 28mg EFX (n=20) Placebo (n=20) Safety Follow - Up Responder Paired Biopsies Week 6 Week 12 Screening Post - Treatment 16 WEEKS Subjects achieving ≥30% relative reduction of hepatic fat at week 12 eligibl

  10. Slide 10: Baseline Demographics

    Slide 10: Baseline Demographics

    - CONFIDENTIAL - BASELINE DEMOGRAPHICS Parameter Mean Placebo (N=21) EFX 28mg (N=19) EFX 50mg (N=20) EFX 70mg (N=20) Age (Years) 52 50 53 53 Sex (Male/Female) 6/15 9/10 10/10 9/11 Weight (kg) 99.6 108.2 103.6 103.1 BMI (kg/m 2 ) 37.6 38.8 36.7 37.2 Liver Fat Content (% by MRI - PDFF) 19.3 21.4 18.3

  11. Slide 11: Patient Disposition

    Slide 11: Patient Disposition

    - CONFIDENTIAL - 11 PATIENT DISPOSITION Full Analysis Set All subjects who were randomized into the study Safety Set All subjects who received at least one dose of study drug MRI - PDFF Evaluable Analysis Set All FAS subjects who have Baseline and Week 12 MRI - PDFF Liver Biopsy Evaluable Analysis S

  12. Slide 12: Substantial Reductions in Liver Fat at Week 12 Across All Dose Groups

    Slide 12: Substantial Reductions in Liver Fat at Week 12 Across All Dose Groups

    - CONFIDENTIAL - SUBSTANTIAL REDUCTIONS IN LIVER FAT AT WEEK 12 ACROSS ALL DOSE GROUPS 12 Source Data: Full Analysis Set -15 -12 -9 -6 -3 0 Placebo 28mg 50mg 70mg - 0% - 12.3 *** - 13.4 *** - 14.1 *** Absolute Reduction (%) *** p<0.001, versus placebo (ANCOVA) LS Mean Reduction in Liver Fat * p<0.05

  13. Slide 13: Magnitude of Liver Fat Reduction

    Slide 13: Magnitude of Liver Fat Reduction

    - CONFIDENTIAL - MAGNITUDE OF LIVER FAT REDUCTION 13 Source Data: MRI - PDFF Evaluable Analysis Set Proportion of Patients Achieving Fat Reduction Thresholds at Week 12 Endpoint Placebo 1 (N=20) 28mg (N=16) 50mg (N=17) 70mg (N=15) Relative Reduction in Liver Fat ≥30% 10% 100% ** 100% *** 100% *** ≥5

  14. Slide 14: Substantial Reductions in Markers of Liver Injury After 16 Weeks

    Slide 14: Substantial Reductions in Markers of Liver Injury After 16 Weeks

    - CONFIDENTIAL - -60% -40% -20% 0% 20% 40% BL W1 W4 W8 W12 W16 W20 Placebo 28 mg 50 mg 70 mg *** *** *** *** *** *** -60% -40% -20% 0% 20% 40% BL W1 W4 W8 W12 W16 W20 Placebo 28mg 50mg 70mg *** *** *** *** ** ** *** *** *** ALT, LS Mean Change from Baseline SUBSTANTIAL REDUCTIONS IN MARKERS OF LIVER

  15. Slide 15: High Response Rates on NASH Resolution After 16 Weeks

    Slide 15: High Response Rates on NASH Resolution After 16 Weeks

    - CONFIDENTIAL - HIGH RESPONSE RATES ON NASH RESOLUTION AFTER 16 WEEKS ACROSS ALL DOSE GROUPS 15 Source Data: Liver Biopsy Evaluable Analysis Set 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning 2 Secondary and exploratory histological endpoints were not powered for sta

  16. Slide 16: High Rates of Fibrosis Improvement After 16 Weeks

    Slide 16: High Rates of Fibrosis Improvement After 16 Weeks

    - CONFIDENTIAL - HIGH RATES OF FIBROSIS IMPROVEMENT AFTER 16 WEEKS ACROSS ALL TREATED PATIENTS 16 Source Data: Liver Biopsy Evaluable Analysis Set 0% 10% 20% 30% 40% 50% 60% 70% Overall 0% 10% 20% 30% 40% 50% 60% 70% Overall Fibrosis Improvement ≥1 Stage and No Worsening of NAS 1,2 1 Improvement in

  17. Slide 17: Rapid Improvements in Fibrosis Biomarkers

    Slide 17: Rapid Improvements in Fibrosis Biomarkers

    - CONFIDENTIAL - -50% -40% -30% -20% -10% 0% 10% BL W1 W4 W8 W12 Placebo 28mg 50mg 70mg *** *** *** Pro - C3, LS Mea n Change from Baseline RAPID IMPROVEMENTS IN FIBROSIS BIOMARKERS CONSISTENT WITH HISTOLOGICAL IMPROVEMENTS 17 Enhanced Liver Fibrosis (ELF) Score, LS Mean *** p<0.001, versus placebo

  18. Slide 18: Fibrosis Improvement in F2-F3 Patients: Half Improved 2 Stages

    Slide 18: Fibrosis Improvement in F2-F3 Patients: Half Improved 2 Stages

    - CONFIDENTIAL - 9% 23% 68% Improved No Change Worsened 9% 23% 68% 2 18 FIBROSIS IMPROVEMENT IN F2 - F3 PATIENTS: HALF OF PATIENTS IMPROVED 2 STAGES All EFX Patients (n=40) Baseline F2 - F3 EFX Patients (n=22) 2 - Stage Improvement (n=11, 50%) 1 - Stage Improvement (n=4, 18%) 10% 35% 55% Source Data

  19. Slide 19: Weight Loss Observed for All Dose Groups

    Slide 19: Weight Loss Observed for All Dose Groups

    - CONFIDENTIAL - -4 -3 -2 -1 0 W16 70mg -4 -3 -2 -1 0 BL W1 W4 W8 W12 W16 Placebo 28mg 50mg 70mg Mean Change in Body Weight (kg) 19 WEIGHT LOSS OBSERVED FOR ALL DOSE GROUPS Mean Change in Body Weight at Week 16 (kg) Source Data: Full Analysis Set Placebo 28mg 50mg - 0.3 - 2.3 - 3.7 + 0.1

  20. Slide 20: Improved Lipoprotein Profile

    Slide 20: Improved Lipoprotein Profile

    - CONFIDENTIAL - -20% -15% -10% -5% 0% W16 - 16% - 2% - 6% 0% * Placebo 28mg 50mg 70mg -25% -20% -15% -10% -5% 0% W16 - 22% - 15% - 17% - 1% *** * ** Placebo 28mg 50mg 70mg 0% 10% 20% 30% 40% 50% W16 + 34% + 39% + 41% + 4% *** *** *** Placebo 28mg 50mg 70mg IMPROVED LIPOPROTEIN PROFILE 20 LDL Choles

  21. Slide 21: Clinically Meaningful Improvements in Glycemic Control After 16 Weeks

    Slide 21: Clinically Meaningful Improvements in Glycemic Control After 16 Weeks

    - CONFIDENTIAL - -0.9 -0.8 -0.7 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 W16 CLINICALLY MEANINGFUL IMPROVEMENTS IN GLYCEMIC CONTROL AFTER 16 WEEKS 21 LS Mean Change From Baseline to Week 16 (%) 1 Absolute change from baseline, % Type 2 DM Patients (N=41) + 0.1 - 0.6 - 0.9 + 0.0 Placebo 28mg 50mg 70mg *

  22. Slide 22: Drug-Related Treatment-Emergent Adverse Events

    Slide 22: Drug-Related Treatment-Emergent Adverse Events

    - CONFIDENTIAL - DRUG - RELATED TREATMENT - EMERGENT ADVERSE EVENTS (TEAE) Most Common (>10%) Drug - Related AEs * Placebo (N=21) All EFX (N=58) EFX 28mg (N=19) EFX 50mg (N=19) EFX 70mg (N=20) Diarrhea 2 (10%) 21 (36%) 5 (26%) 10 (53%) 6 (30%) Nausea 0 (0%) 20 (34%) 6 (32%) 4 (21%) 10 (50%) Increase

  23. Slide 23: NASH Development Landscape: Fibrosis Improvement

    Slide 23: NASH Development Landscape: Fibrosis Improvement

    - CONFIDENTIAL - NASH DEVELOPMENT LANDSCAPE: FIBROSIS IMPROVEMENT 23 Proportion of Subjects with ≥1 Stage Improvement in Fibrosis and No Worsening of NAS 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (201 8) Pbo All Pbo 1

  24. Slide 24: NASH Development Landscape: NASH Resolution

    Slide 24: NASH Development Landscape: NASH Resolution

    - CONFIDENTIAL - Pbo 0.8g 1.2g Increasing dosing duration NASH DEVELOPMENT LANDSCAPE: NASH RESOLUTION 24 Proportion of Subjects with Resolution of NASH and No Worsening of Fibrosis 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Trea

  25. Slide 25: FGF21 Development Landscape

    Slide 25: FGF21 Development Landscape

    - CONFIDENTIAL - FGF21 DEVELOPMENT LANDSCAPE Noninvasive Measures: Percent Change From Baseline to End of Study Akero (EFX) 16 weeks BMS ( Pegbelfermin ) 16 weeks 89Bio (BIO89 - 100) 12 weeks Dose pbo 28 QW 50 QW pbo 20 QW 10 QD pbo 18 QW 27 QW 36 Q2W Patient Population Biopsy - confirmed NASH Biops

  26. Slide 26: Peripheral FGFR1c Activation

    Slide 26: Peripheral FGFR1c Activation

    - CONFIDENTIAL - -20% 0% 20% 40% 60% 80% 100% -50% -40% -30% -20% -10% 0% 10% 26 PERIPHERAL FGFR1c ACTIVATION Note: These data are derived from different clinical trials at different points in time, with differences in trial design and patient populations. No head - to - head clinical trials have be

  27. Slide 27: FGF21 Development Landscape: Summary

    Slide 27: FGF21 Development Landscape: Summary

    - CONFIDENTIAL - 27 FGF21 DEVELOPMENT LANDSCAPE: SUMMARY Consideration Fc - FGF21 Fusion Protein (Akero) Pegylated FGF21 (BMS or 89Bio) Patient Population: NASH diagnosed only by biopsy; NASH patients have more advanced disease and worse comorbidities Biopsy - confirmed NASH BMS: biopsy - confirmed

  28. Slide 28: BALANCED F4 Cohort Expansion (Cohort C) Trial Design

    Slide 28: BALANCED F4 Cohort Expansion (Cohort C) Trial Design

    - CONFIDENTIAL - * BALANCED F4 COHORT EXPANSION (COHORT C) TRIAL DESIGN 28 Number of Subjects 30 Primary Endpoint Safety & tolerability BALANCED study expanded to include cohort of patients with compensated cirrhosis (F4), Child - Pugh Class A; results expected to inform long - term development in c

  29. Slide 29: Phase 2b Trial (HARMONY) Design

    Slide 29: Phase 2b Trial (HARMONY) Design

    - CONFIDENTIAL - 29 PHASE 2B TRIAL (HARMONY) DESIGN Screening Randomization EFX 28mg Placebo 24 Weeks EFX 50 mg Placebo EFX * Long - Term Safety Follow - Up Phase 2b MRI - PDFF Liver Biopsy * Phase 3 protocol finalization expected after end - of - Phase 2 meeting with FDA Key Inclusion Criteria • F2

  30. Slide 30: Strong Financial Position

    Slide 30: Strong Financial Position

    - CONFIDENTIAL - 30 STRONG FINANCIAL POSITION ~$ 106M Raised in aggregate gross proceeds ~$ 292M COMPLETED UPSIZED FOLLOW - ON OFFERING July 10, 2020 ~$ 216M Raised in aggregate gross proceeds

  31. Slide 31: Consistent Record of Milestone Delivery

    Slide 31: Consistent Record of Milestone Delivery

    - CONFIDENTIAL - March June BALANCED F1 - F3 MRI - PDFF Read - out June ~$106M Upsized IPO July BALANCED Initiation BALANCED F1 - F3 Liver Biopsy Read - out 2019 2020 CONSISTENT RECORD OF MILESTONE DELIVERY 31 July ~$216M Upsized Offering 1H BALANCED F4 Liver Biopsy Read - out 1H HARMONY F2 - F3 Ph2

  32. Slide 32: Efruxifermin After 16 Weeks: Potentially Foundational NASH Monotherapy

    Slide 32: Efruxifermin After 16 Weeks: Potentially Foundational NASH Monotherapy

    - CONFIDENTIAL - Safety & Tolerability 32 EFRUXIFERMIN AFTER 16 WEEKS: POTENTIALLY FOUNDATIONAL NASH MONOTHERAPY Improved Non - Invasive Markers Improved NASH Comorbidities Improved Histology • 63 - 72% relative reduction in liver fat • ~40% reduction in liver enzymes • Reduction in ELF and Pro - C3

  33. Slide 33: A Global Disease, A Pioneering Treatment

    Slide 33: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment NASDAQ: AKRO

Source: SEC EDGAR · 8-K filed Jan 11, 2021

More decks from Akero Therapeutics Inc